Ocular Therapeutix
Yahoo Finance • 9 months ago
Ocular Therapeutix™ Announces Proposed Public Offering of Common Stock
Ocular Therapeutix, Inc. BEDFORD, Mass., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix™, Inc. (Nasdaq: OCUL) (the “Company”), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative... Full story
Yahoo Finance • 10 months ago
Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences
BEDFORD, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of th... Full story
Yahoo Finance • 10 months ago
Ocular Therapeutix™ Provides Third Quarter 2023 Financial Results and Corporate Update
FDA Agrees to Overall Design of the First Pivotal Trial for AXPAXLI in Wet AMD under a Special Protocol Assessment; Expect First Subject Dosed by Year-End Top-line Data from U.S.-based HELIOS Trial Evaluating AXPAXLI for Treatment of Non-... Full story
Yahoo Finance • 11 months ago
Ocular Therapeutix™ Receives FDA Agreement Under Special Protocol Assessment (SPA) for its First Pivotal Clinical Trial of OTX-TKI in Wet AMD
The first subject expected to be dosed by year-end Company announces OTX-TKI trade name AXPAXLI BEDFORD, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formu... Full story
Yahoo Finance • 11 months ago
Ocular Therapeutix™ To Report Third Quarter 2023 Financial Results
BEDFORD, Mass., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of t... Full story
Yahoo Finance • 12 months ago
Ocular Therapeutix™ Announces Initiation of its First Pivotal Clinical Trial of OTX-TKI in Wet AMD
BEDFORD, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development and commercialization of innovative therapies for diseases and conditions of t... Full story
Yahoo Finance • last year
10 Best Rising Penny Stocks to Buy
In this article, we will take a look at the 10 best rising penny stocks to buy. To see more such companies, go directly to 5 Best Rising Penny Stocks to Buy. Amid too much volatility everyone seems to avoid small companies that are workin... Full story
Yahoo Finance • last year
Ocular Therapeutix™ Announces Appointment of New Board Member
BEDFORD, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of... Full story
Yahoo Finance • last year
Ocular Therapeutix™ Announces 12-Month Topline Data from Ongoing U.S.-Based Phase 1 Clinical Trial Evaluating OTX-TKI for Treatment of Wet AMD
OTX-TKI maintained vision and CSFT comparable to aflibercept every eight weeks, with 89% reduction in treatment burden over a 12-month period OTX-TKI demonstrated no drug-related ocular or systemic serious adverse events in the trial thro... Full story
Yahoo Finance • last year
3 Low-Priced Stocks -- And How I'm Trading Them
Small-cap stocks are lagging with a decline of about 1%, and there is minimal, speculative action. In a healthier market environment, I would be focused on buying stocks that are showing relative strength, and I would chase them higher, bu... Full story
Yahoo Finance • last year
Ocular Therapeutix™ To Present Data at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
BEDFORD, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of... Full story
Yahoo Finance • last year
Ocular Therapeutix™ To Report First Quarter 2023 Financial Results
BEDFORD, Mass., April 24, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of... Full story
Yahoo Finance • 2 years ago
Ocular Therapeutix™ Provides Fourth Quarter and Year-End 2022 Results and Corporate Update
Presented Positive 10-month Interim Data from the U.S.-based Phase 1 Clinical Trial of OTX-TKI (axitinib intravitreal implant) for the Treatment of Wet AMD at the Angiogenesis, Exudation, and Degeneration Annual 2023 Meeting Initiated Pha... Full story
Yahoo Finance • 2 years ago
Ocular Therapeutix™ to Present at Cowen’s 43rd Annual Healthcare Conference
BEDFORD, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of t... Full story
Yahoo Finance • 2 years ago
Ocular Therapeutix™ To Report Fourth Quarter and Year-End 2022 Financial Results
BEDFORD, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of t... Full story
Yahoo Finance • 2 years ago
Ocular Therapeutix™ Announces Interim 10-month Data from the Ongoing U.S. Phase 1 Clinical Trial Evaluating OTX-TKI for the Treatment of Wet AMD
All OTX-TKI treated subjects who were rescue-free at the Month 7 interim analysis remained rescue-free, extending the 73% rescue-free rate up to Month 10 CSFT and BCVA measurements at 10 months were comparable between OTX-TKI treated subj... Full story
Yahoo Finance • 2 years ago
Ocular Therapeutix™ Provides 2022 Year End Corporate Update and Reviews Expected 2023 Milestones
Dextenza® Net Product Revenue in the Fourth Quarter of 2022 is Estimated to be $13.6 million, Growing Approximately 14% Over Previous Quarter and Approximately 11% Over Same Quarter of Prior Year Dextenza Net Product Revenue for the Year... Full story
Yahoo Finance • 2 years ago
Ocular Therapeutix™ Reports Second Quarter 2022 Financial Results and Business Update
Interim Data from the U.S.-based Clinical Trial for OTX-TKI for the Treatment of Wet AMD to be Presented at American Academy of Ophthalmology (AAO) in the Third Quarter of 2022 DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg Recorded Q... Full story
Yahoo Finance • 2 years ago
Ocular Therapeutix™ Announces Organizational Changes to Support Development for Retinal Diseases
Peter K. Kaiser, M.D., a world-renowned ophthalmologist and retinal disease expert, to serve as Chief Medical Advisor – Retina Rabia Gurses Ozden, M.D. promoted to Chief Medical Officer Michael Goldstein, M.D. to transition from Chief Me... Full story
